FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Sex differences in the clinical presentation and therapy of multiple sclerosis

Polne razlike u kliničkoj slici i terapiji multiple skleroze

Thumbnail
2016
2723.pdf (252.6Kb)
Authors
Nacka-Aleksić, Mirjana
Article (Published version)
Metadata
Show full item record
Abstract
Multiple sclerosis (MS) is more prevalent in women than in men, with the female to male ratio in the prevalence of MS constantly increasing. Besides, sex appears to affect the development, progression, clinical manifestation and therapy response in MS. These sex differences, most likely, emerge from the genetic, epigenetic and hormonal differences between the sexes, differences in environmental exposure and/or susceptibility to certain factors, as well as from the biological differences in the female and male immune and nervous system. Therefore, sex differences in all of these aspects need to be taken into consideration when designing and interpreting research findings related to MS, and particularly in development of new therapeutic strategies and designing of clinical drug trials. Understanding the mechanisms underlying sex differences in the pathogenesis and/or therapy response in MS could also narrow the gap in our knowledge of the pathogenesis/therapy of a broad spectrum of other... autoimmune diseases that are characterized by sexual dimorphism in the prevalence and/or clinical presentation.

Multipla skleroza (MS) se češće javlja kod žena nego kod muškaraca i disproporcija između obolevanja žena i muškaraca od ove bolesti pokazuje tendenciju stalnog rasta. Pol ima kritičnu ulogu u razvoju, progresiji, kliničkim manifestacijama MS i odgovoru na terapiju. Ove razlike su, najverovatnije, posledica delovanja genetskih, epigenetskih i hormonskih faktora, razlika u izloženosti pojedinim sredinskim faktorima, kao i bioloških razlika između imunskog i nervnog sistema žena i muškaraca. Polne razlike u svim ovim aspektima se moraju uzeti u obzir prilikom dizajniranja i tumačenja rezultata istraživanja vezanih za patogenezu MS, a posebno prilikom razvoja novih terapijskih strategija i kliničkih istraživanja lekova namenjenih lečenju ove bolesti. Razumevanje mehanizama koji stoje u osnovi polnih razlika u patogenezi i/ili odgovoru na terapiju u MS bi moglo biti relevantno i za širi spektar autoimunskih bolesti u kojima je izražen polni dimorfizam u incidenci i prevalenci i/ili kliničk...im manifestacijama bolesti.

Keywords:
sex differences / multiple sclerosis / DMT / polne razlike / multipla skleroza / DMT
Source:
Arhiv za farmaciju, 2016, 66, 4, 135-146
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd
Funding / projects:
  • Immune system plasticity during aging: Immunomodulatory capacity of oestrogens (RS-175050)

DOI: 10.5937/arhfarm1604135N

ISSN: 0004-1963

Scopus: 2-s2.0-85019108164
[ Google Scholar ]
1
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2725
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Nacka-Aleksić, Mirjana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2725
AB  - Multiple sclerosis (MS) is more prevalent in women than in men, with the female to male ratio in the prevalence of MS constantly increasing. Besides, sex appears to affect the development, progression, clinical manifestation and therapy response in MS. These sex differences, most likely, emerge from the genetic, epigenetic and hormonal differences between the sexes, differences in environmental exposure and/or susceptibility to certain factors, as well as from the biological differences in the female and male immune and nervous system. Therefore, sex differences in all of these aspects need to be taken into consideration when designing and interpreting research findings related to MS, and particularly in development of new therapeutic strategies and designing of clinical drug trials. Understanding the mechanisms underlying sex differences in the pathogenesis and/or therapy response in MS could also narrow the gap in our knowledge of the pathogenesis/therapy of a broad spectrum of other autoimmune diseases that are characterized by sexual dimorphism in the prevalence and/or clinical presentation.
AB  - Multipla skleroza (MS) se češće javlja kod žena nego kod muškaraca i disproporcija između obolevanja žena i muškaraca od ove bolesti pokazuje tendenciju stalnog rasta. Pol ima kritičnu ulogu u razvoju, progresiji, kliničkim manifestacijama MS i odgovoru na terapiju. Ove razlike su, najverovatnije, posledica delovanja genetskih, epigenetskih i hormonskih faktora, razlika u izloženosti pojedinim sredinskim faktorima, kao i bioloških razlika između imunskog i nervnog sistema žena i muškaraca. Polne razlike u svim ovim aspektima se moraju uzeti u obzir prilikom dizajniranja i tumačenja rezultata istraživanja vezanih za patogenezu MS, a posebno prilikom razvoja novih terapijskih strategija i kliničkih istraživanja lekova namenjenih lečenju ove bolesti. Razumevanje mehanizama koji stoje u osnovi polnih razlika u patogenezi i/ili odgovoru na terapiju u MS bi moglo biti relevantno i za širi spektar autoimunskih bolesti u kojima je izražen polni dimorfizam u incidenci i prevalenci i/ili kliničkim manifestacijama bolesti.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Sex differences in the clinical presentation and therapy of multiple sclerosis
T1  - Polne razlike u kliničkoj slici i terapiji multiple skleroze
VL  - 66
IS  - 4
SP  - 135
EP  - 146
DO  - 10.5937/arhfarm1604135N
ER  - 
@article{
author = "Nacka-Aleksić, Mirjana",
year = "2016",
abstract = "Multiple sclerosis (MS) is more prevalent in women than in men, with the female to male ratio in the prevalence of MS constantly increasing. Besides, sex appears to affect the development, progression, clinical manifestation and therapy response in MS. These sex differences, most likely, emerge from the genetic, epigenetic and hormonal differences between the sexes, differences in environmental exposure and/or susceptibility to certain factors, as well as from the biological differences in the female and male immune and nervous system. Therefore, sex differences in all of these aspects need to be taken into consideration when designing and interpreting research findings related to MS, and particularly in development of new therapeutic strategies and designing of clinical drug trials. Understanding the mechanisms underlying sex differences in the pathogenesis and/or therapy response in MS could also narrow the gap in our knowledge of the pathogenesis/therapy of a broad spectrum of other autoimmune diseases that are characterized by sexual dimorphism in the prevalence and/or clinical presentation., Multipla skleroza (MS) se češće javlja kod žena nego kod muškaraca i disproporcija između obolevanja žena i muškaraca od ove bolesti pokazuje tendenciju stalnog rasta. Pol ima kritičnu ulogu u razvoju, progresiji, kliničkim manifestacijama MS i odgovoru na terapiju. Ove razlike su, najverovatnije, posledica delovanja genetskih, epigenetskih i hormonskih faktora, razlika u izloženosti pojedinim sredinskim faktorima, kao i bioloških razlika između imunskog i nervnog sistema žena i muškaraca. Polne razlike u svim ovim aspektima se moraju uzeti u obzir prilikom dizajniranja i tumačenja rezultata istraživanja vezanih za patogenezu MS, a posebno prilikom razvoja novih terapijskih strategija i kliničkih istraživanja lekova namenjenih lečenju ove bolesti. Razumevanje mehanizama koji stoje u osnovi polnih razlika u patogenezi i/ili odgovoru na terapiju u MS bi moglo biti relevantno i za širi spektar autoimunskih bolesti u kojima je izražen polni dimorfizam u incidenci i prevalenci i/ili kliničkim manifestacijama bolesti.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Sex differences in the clinical presentation and therapy of multiple sclerosis, Polne razlike u kliničkoj slici i terapiji multiple skleroze",
volume = "66",
number = "4",
pages = "135-146",
doi = "10.5937/arhfarm1604135N"
}
Nacka-Aleksić, M.. (2016). Sex differences in the clinical presentation and therapy of multiple sclerosis. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 66(4), 135-146.
https://doi.org/10.5937/arhfarm1604135N
Nacka-Aleksić M. Sex differences in the clinical presentation and therapy of multiple sclerosis. in Arhiv za farmaciju. 2016;66(4):135-146.
doi:10.5937/arhfarm1604135N .
Nacka-Aleksić, Mirjana, "Sex differences in the clinical presentation and therapy of multiple sclerosis" in Arhiv za farmaciju, 66, no. 4 (2016):135-146,
https://doi.org/10.5937/arhfarm1604135N . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB